Oppenheimer Holdings, Inc. assumed coverage on shares of Lion Biotechnologies, Inc. (NASDAQ:IOVA) in a research report report published on Friday morning. The brokerage issued an outperform rating and a $13.00 price target on the biotechnology company’s stock.

A number of other research analysts also recently issued reports on IOVA. Cowen and Company reiterated a buy rating on shares of Lion Biotechnologies in a report on Saturday, May 20th. Zacks Investment Research downgraded Lion Biotechnologies from a buy rating to a hold rating in a report on Thursday, August 3rd. HC Wainwright reiterated a buy rating and set a $16.00 price objective on shares of Lion Biotechnologies in a report on Wednesday, June 7th. FBR & Co reiterated a buy rating on shares of Lion Biotechnologies in a report on Thursday, May 18th. Finally, Jefferies Group LLC reiterated a buy rating and set a $11.00 price objective on shares of Lion Biotechnologies in a report on Thursday, May 18th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock currently has an average rating of Buy and an average target price of $13.88.

Lion Biotechnologies (NASDAQ:IOVA) opened at 5.60 on Friday. The stock’s market cap is $351.05 million. The firm’s 50-day moving average price is $6.24 and its 200 day moving average price is $6.86. Lion Biotechnologies has a 1-year low of $4.90 and a 1-year high of $9.58.

TRADEMARK VIOLATION WARNING: “Lion Biotechnologies, Inc. (IOVA) Now Covered by Analysts at Oppenheimer Holdings, Inc.” was published by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/08/08/lion-biotechnologies-inc-iova-now-covered-by-analysts-at-oppenheimer-holdings-inc.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Victory Capital Management Inc. bought a new position in Lion Biotechnologies during the second quarter worth $19,013,000. Legal & General Group Plc bought a new position in Lion Biotechnologies during the second quarter worth $103,000. Bank of New York Mellon Corp bought a new position in Lion Biotechnologies during the second quarter worth $1,796,000. State of Wisconsin Investment Board bought a new position in Lion Biotechnologies during the second quarter worth $287,000. Finally, Rhumbline Advisers bought a new position in Lion Biotechnologies during the second quarter worth $468,000. Hedge funds and other institutional investors own 77.82% of the company’s stock.

About Lion Biotechnologies

Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.

Analyst Recommendations for Lion Biotechnologies (NASDAQ:IOVA)

Receive News & Ratings for Lion Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lion Biotechnologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.